Are you an attendee? You will have received an email from noreply@spotme.com (check your junk) that provides you with access to the platform and the meeting.
Are you a presenter? You will have received a calendar invite and a direct Zoom link.
Need help quickly? Send an email to the GOC staff at enquiry@gyneoncology.ca or text 1-888-496-3662.
AGM highlights new advancements in research and practice in the field of gynecologic oncology. This engaging professional development event offers access to world-renowned speakers, plenary talks, abstract presentations, and so much more.
Upon completion of the conference, participants will be able to:
This is a virtual meeting. Please note that all times in the agenda on this site are in PST.
30
-
35
35
-
35
At the end of this session, participants will:
1. Understand the impact of racism on Indigenous health and health care.
2. Identify the human rights basis of Joyce's Principle.
3. Critically reflect on opportunities for action to improve health care quality for Indigenous Peoples.
35
-
40
40
-
05
At the end of this session, participants should be able to evaluate the following studies: *Oncologic and pregnancy outcomes after fertility sparing surgery for stage I, low grade endometrioid ovarian cancer - Brenna E. Swift MD, MASc. *Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative - Sarah J. Mah MD MSc FRCSC. *Quality of end-of-life care for women with gynecologic malignancies in Ontario, Canada: a 13-year population-based retrospective analysis - Sarah J. Mah MD MSc FRCSC. *Apixaban for Postoperative Thromboprophylaxis as Standard of Care for Gynecologic Oncology Patients: A Real-World Data Study - Elisabeth Spenard MD, MSc. *Cost-analysis of an enhanced recovery program after minimally invasive gynecologic oncology surgery - Cristina Mitric MD.
05
-
50
Sponsor Symposium (15 min)
50
-
55
55
-
00
00
-
15
At the end of this session, participants should be able to evaluate the following studies: * Laparoscopic repair of obturator nerve injury at the time of pelvic lymphadenectomy - Revital Linder MD. * Predictors of Supportive Care in Young Women Diagnosed with a Gynecological Malignancy - Catriona J Buick RN, PhD, CON(C).
15
-
45
At the end of this session, participants should be able to evaluate the following studies: * Are mismatch repair deficient endometrial cancer recurrences more salvageable than intact cohort? - Rachel Soyoun Kim MD, MHSc, FRCSC. * The effect of transversus abdominis plane block on postoperative opioid use in gynecologic oncology patients undergoing laparotomy with Enhanced Recovery After Surgery (ERAS). - Kristin A Black MD FRCSC. * Are uterine manipulators harmful in minimally invasive surgery (MIS) for endometrial cancer? A retrospective cohort study. - Maxime Côté MD.
45
-
45
50
-
00
00
-
15
This will be a panel of experts that will help you discover the world of surgical clinical trials from ideation to application. They will also cover constraints such as funding. The AGO perspective: Dr. Andreas Dubois. Surgical Trials in Cervix Cancer: The SHAPE of the future, Dr. Marie Plante. Surgical Gynecological Cancer Trials and the CCTG: Dr. Mark Carey.
At the end of this session, participants will be able to: 1. Describe the framework leading to clinical trial approval in Canada. 2. Review recent successful Canadian initiated surgical clinical trials. 3. Discuss ways to engage more Canadian clinicians and centres in surgical clinical trials.
15
-
00
The battle is on! Two debators will take a pro vs. con position on secondary cytoreductive surgery for recurrent ovarian cancer. Pros. Dr Andreas DuBois. vs. Cons. Dr Susie Lau
At the end of this session, participants will be able to: 1. Review available current literature related to secondary cytoreductive surgery in recurrent ovarian cancer. 2. Identify potential patients and indications for this procedure. 3. Discuss the clinical relevance and impact in the Canadian setting.
00
-
45
At the end of this session, participants will be able to: 1. Summarize the vision/mission and goals of OvCan. 2. Review the trial that has applied a “one-two punch” by combining the PARP inhibitor Veliparib with a second drug, Navitoclax. The two-pronged goal of this trial: to expand the benefits of this therapy to more women; and to prolong its effects in managing recurrences of the disease. 3. Review the NEO Trial which aims to determine how early this new therapy can be introduced in an ovarian cancer patient’s journey. The trial will compare the use of the PARP inhibitor Olaparib to standard chemotherapy applied immediately before and after surgery as a way to delay disease progression and reduce recurrences.
45
-
55
55
-
00
05
-
05
For GOC Members Only
Presidential Talk
The Joyce Echaquan Inquiry: Learning and Unlearning in Indigenous Health by Dr. Marcia Anderson
At the end of this session, participants will:
Oral Abstract Presentations
3 min / 3 slides
At the end of this session, participants should be able to evaluate the following studies:
Video Abstracts
At the end of this session, participants should be able to evaluate the following studies:
Oral Abstract Presentations
7-min presentations and 3-min Q&A
At the end of this session, participants should be able to evaluate the following studies:
Surgical Clinical Trials
Challenges and Opportunities
This is a panel of experts that will help you discover the world of surgical clinical trials from ideation to application. They will also cover constraints such as funding. The AGO perspective: Dr. Andreas Dubois. Surgical Trials in Cervix Cancer: The SHAPE of the future, Dr. Marie Plante. Surgical Gynecological Cancer Trials and the CCTG: Dr. Mark Carey.
At the end of this session, participants will be able to:
DeskTop Trials and Secondary Cytoreduction Debate
The battle is on!
Two debators will take a pro vs. con position on secondary cytoreductive surgery for recurrent ovarian cancer. Pros. Dr Andreas DuBois. vs. Cons. Dr Susie Lau.
At the end of this session, participants will be able to:
OvCAN Symposium
Dr. Barbara Vanderhyden, Dr. Stephanie Lheureux. Dr. Helen MacKay, Dr. Alicia Tone.
At the end of this session, participants will be able to:
The Society of Gynecologic Oncology of Canada (GOC) invites researchers from around the world to submit abstracts for presentation at the 43rd Annual General Meeting (AGM) which will be held virtually on June 10, 2022.
The meeting will feature a wide range of exciting talks, discussions, and networking opportunities with experts, researchers, trainees and leaders in the field of gynecologic oncology. Investigators at all career stages are encouraged to submit as many abstracts as you would like.
Your best ranking abstract will be included in the competition for oral presentation, all other abstracts will be presented as posters and/or video presentations.
The Call for Abstracts is closed.
Submissions will be evaluated using the following criteria (each on a five-point scale):
Features that increase the likelihood of results being trustworthy:
Video presenters
Your video submission will be presented during the live portion of the virtual meeting on the following date: Friday June 10, 2022, between 10:05 – 10:20am PST. Please make yourself available for the full presentation as you will have a live 2-minute Q&A session at the end of your video presentation.
Your video will be judged by members of the GOC community and will be eligible for a Best Video award. Award announcements will take place on Friday, June 10, 2022, at 2:45pm PST.
What we need from you:
Oral Presenters
The oral presentations will be presented in two categories: 3 minutes / 3 slides and the 7 minutes / 3 minutes Q&A. Please refer to the acceptance email that was sent to you to know about your category (check your junk folder).
We ask that you are present for the entire session and be available to answer live questions following the distillation presentation.
What we need from you:
Important
Poster Presenters
Your ePoster submission will be available for viewing by the AGM Virtual meeting participants from June 7, 2022, at 12pm PST until June 10, 2022, at 12pm PST and will be scored by the meeting participants.
The ePosters will be eligible for a Best Poster award. Award announcements will take place on Friday, June 10, 2022, at 2:45pm PST.
Questions? Send us an email at enquiry@gyneoncology.ca or text us at 1-888-496-3662.
Member Price
This ticket includes members in the following categories: emeritus, nurses, other healthcare professionals and resident associates
Public Price
This option is free for representatives up to the number of spots reserved for your organization as per your sponsorship level. If you are not on the final list submitted by your organization, you will be asked to attend as an "Other Non-Members." Connect with your organization's representative before registering.
Public Price
This ticket is only open to those who have received a poster/video acceptance for their submitted abstract.